Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.47 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406482 | 1.00 | SIGMAR1 (0.47) | SIGMAR1SLC18A3IDO1TDO2ALDH1A1 | |
| SCHEMBL5397934 | 0.87 | SIGMAR1 (0.52) | SIGMAR1SLC18A3IDO1TDO2ALDH1A1 | |
| SCHEMBL5397936 | 0.87 | SIGMAR1 (0.52) | SIGMAR1SLC18A3IDO1TDO2ALDH1A1 | |
| SCHEMBL6336998 | 0.85 | SIGMAR1 (0.44) | SIGMAR1SLC18A3ALDH1A1TP53CYP1A2 | |
| SCHEMBL27167028 | 0.81 | ALDH1A1 (0.52) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4976403 | 0.79 | OPRL1 (0.46) | ALDH1A1OPRL1 | |
| SCHEMBL4976407 | 0.79 | OPRL1 (0.46) | ALDH1A1OPRL1 | |
| SCHEMBL4979532 | 0.79 | SIGMAR1 (0.46) | SIGMAR1SLC18A3ALDH1A1TP53CYP1A2 | |
| SCHEMBL4979536 | 0.79 | SIGMAR1 (0.46) | SIGMAR1SLC18A3ALDH1A1TP53CYP1A2 | |
| SCHEMBL4979770 | 0.78 | SLC18A3 (0.42) | SIGMAR1SLC18A3ALDH1A1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279486-B2 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277659-A1 | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as ORL1-receptor antagonists | OPRL1, OGFRL1, ORMDL3 | SIGMAR1 10/4885SLC18A3 3734/4885IDO1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.